{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:17:58Z","timestamp":1793139478845,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.hoc.2025.02.005","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T09:23:37Z","timestamp":1743413017000},"page":"617-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)"],"prefix":"10.1016","volume":"39","author":[{"given":"Jerry C.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William T.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.hoc.2025.02.005_bib1","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.005_bib2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.005_bib3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.005_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"10.1016\/j.hoc.2025.02.005_bib5","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.02.005_bib6","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(21)00366-5","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis","volume":"9","author":"Setiadi","year":"2022","journal-title":"Lancet Haematol"},{"issue":"16","key":"10.1016\/j.hoc.2025.02.005_bib8","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.005_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.005_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41419-021-03428-x","article-title":"DAMPs released by pyroptotic cells as major contributors and therapeutic targets for CAR-T-related toxicities","volume":"12","author":"Deng","year":"2021","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.005_bib11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/bloodadvances.2019001272","article-title":"Identification of germline variants in adults with hemophagocytic lymphohistiocytosis","volume":"4","author":"Miller","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.005_bib12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/imr.13298","article-title":"Hemophagocytic lymphohistiocytosis: a disorder of T cell activation, immune regulation, and distinctive immunopathology","volume":"322","author":"Jordan","year":"2024","journal-title":"Immunol Rev"},{"issue":"20","key":"10.1016\/j.hoc.2025.02.005_bib13","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.02.005_bib14","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2023-178283","article-title":"CD22 CAR T cell-related IEC-HS is associated with an IFN-\u03b3 cytokine signature","volume":"142","author":"Srinagesh","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2025.02.005_bib15","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.02.005_bib16","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1080\/10428194.2021.1881507","article-title":"Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature","volume":"62","author":"Major","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.005_bib17","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.16155","article-title":"Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy","volume":"187","author":"Hashmi","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2025.02.005_bib18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jcyt.2023.06.008","article-title":"A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy","volume":"25","author":"Zu","year":"2023","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.hoc.2025.02.005_bib19","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.3324\/haematol.2023.284784","article-title":"Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series","volume":"109","author":"Scala","year":"2024","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.hoc.2025.02.005_bib20","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.005_bib21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood.2019003664","article-title":"Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect","volume":"136","author":"Carvelli","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2025.02.005_bib22","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1182\/blood-2014-05-573105","article-title":"Synergistic defects of different molecules in the cytotoxic pathway lead to clinical familial hemophagocytic lymphohistiocytosis","volume":"124","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2025.02.005_bib23","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1182\/blood-2011-07-370148","article-title":"Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2025.02.005_bib24","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood.2020008206","article-title":"Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis","volume":"136","author":"Miller","year":"2020","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.02.005_bib25","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/bloodadvances.2023011733","article-title":"Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in patients with T- and\/or NK-cell lymphoma","volume":"8","author":"Liu","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.005_bib26","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2025.02.005_bib27","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"issue":"27","key":"10.1016\/j.hoc.2025.02.005_bib28","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2025.02.005_bib29","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8057","article-title":"Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)","volume":"38","author":"Ahmed","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.005_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.005_bib31","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/10428194.2021.2024817","article-title":"Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed\/refractory diffuse large B-Cell lymphoma","volume":"63","author":"Kim","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.hoc.2025.02.005_bib32","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"17","key":"10.1016\/j.hoc.2025.02.005_bib33","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1182\/bloodadvances.2022008937","article-title":"Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome","volume":"7","author":"Bhaskar","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.hoc.2025.02.005_bib34","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3324\/haematol.2022.281455","article-title":"Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy","volume":"108","author":"Song","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.005_bib35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-024-01119-2","article-title":"Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management","volume":"14","author":"Khurana","year":"2024","journal-title":"Blood Cancer J"},{"issue":"23","key":"10.1016\/j.hoc.2025.02.005_bib36","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.hoc.2025.02.005_bib37","doi-asserted-by":"crossref","first-page":"E374","DOI":"10.1002\/ajh.26668","article-title":"Hemophagocytic lymphohistiocytosis secondary to CAR-T cells: update from the FDA and Vizient databases","volume":"97","author":"Priyadarshini","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.005_bib38","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.005_bib39","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.21423","article-title":"Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis","volume":"50","author":"Allen","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"10.1016\/j.hoc.2025.02.005_bib40","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2025.02.005_bib47","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.02.005_bib48","article-title":"A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed\/refractory multiple myeloma patients treated with CAR-T cells","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.005_bib49","first-page":"160","article-title":"Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma","volume":"51","author":"Zu","year":"2022","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"issue":"20","key":"10.1016\/j.hoc.2025.02.005_bib50","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1182\/bloodadvances.2023010708","article-title":"Free interleukin-18 is elevated in CD22 CAR T-cell-associated hemophagocytic lymphohistiocytosis-like toxicities","volume":"7","author":"Rocco","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.005_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13613-024-01247-9","article-title":"Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort","volume":"14","author":"Le Cacheux","year":"2024","journal-title":"Ann Intensive Care"},{"issue":"7","key":"10.1016\/j.hoc.2025.02.005_bib52","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.005_bib53","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"24","key":"10.1016\/j.hoc.2025.02.005_bib54","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.005_bib55","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3324\/haematol.2023.283478","article-title":"Ruxolitinib-based regimen in children with primary hemophagocytic lymphohistiocytosis","volume":"109","author":"Ge","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2025.02.005_bib56","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.3324\/haematol.2020.253781","article-title":"A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis","volume":"106","author":"Zhang","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.005_bib57","doi-asserted-by":"crossref","first-page":"E103","DOI":"10.1002\/ajh.26091","article-title":"Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis","volume":"96","author":"Boonstra","year":"2021","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.hoc.2025.02.005_bib58","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2217\/imt-2020-0116","article-title":"Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function","volume":"12","author":"Wei","year":"2020","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.005_bib59","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/10428194.2022.2148209","article-title":"Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy","volume":"64","author":"Gu","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.005_bib60","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.hoc.2025.02.005_bib61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2022.01.070","article-title":"Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells","volume":"595","author":"Xu","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"19","key":"10.1016\/j.hoc.2025.02.005_bib62","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.005_bib63","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.005_bib64","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.005_bib65","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-\u03b3 blockade in CAR T-cell therapy-associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.hoc.2025.02.005_bib66","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.005_bib67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-024-01048-0","article-title":"Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"14","author":"Costa","year":"2024","journal-title":"Blood Cancer J"},{"issue":"23","key":"10.1016\/j.hoc.2025.02.005_bib68","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.02.005_bib69","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4049\/jimmunol.1302282","article-title":"Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis","volume":"192","author":"Johnson","year":"2014","journal-title":"J Immunol"},{"issue":"25","key":"10.1016\/j.hoc.2025.02.005_bib70","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.02.005_bib71","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood-2006-04-015230","article-title":"The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies","volume":"109","author":"Traversari","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.005_bib72","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2025.02.005_bib73","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2025.02.005_bib74","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.005_bib75","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.02.005_bib76","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.005_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004185","article-title":"To go or not to go? Biological logic gating engineered T cells","volume":"10","author":"Abbott","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2025.02.005_bib78","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.ymthe.2024.02.022","article-title":"Inhibitory CARs fail to protect from immediate T cell cytotoxicity","volume":"32","author":"Funk","year":"2024","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.hoc.2025.02.005_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci Adv"},{"issue":"5","key":"10.1016\/j.hoc.2025.02.005_bib80","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.005_bib81","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.hoc.2025.02.005_bib82","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.hoc.2025.02.005_bib83","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2025.02.005_bib84","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.02.005_bib85","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2025.02.005_bib86","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.hoc.2025.02.005_bib87","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"issue":"10435","key":"10.1016\/j.hoc.2025.02.005_bib88","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D\u2019Angelo","year":"2024","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.hoc.2025.02.005_bib89","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.005_bib90","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2025.02.005_bib91","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"10379","key":"10.1016\/j.hoc.2025.02.005_bib92","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.hoc.2025.02.005_bib93","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.hoc.2025.02.005_bib94","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"issue":"12","key":"10.1016\/j.hoc.2025.02.005_bib95","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:42:30Z","timestamp":1762314150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0889858825000206"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.02.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}